diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12920diaendo-12920Research ArticleОбзорыReviewРаспространённость нарушений углеводного обмена у пациентов с терминальной почечной недостаточностью на терапии гемодиализомPrevalence of carbohydrate metabolism disorders in patients with end-stage renal disease on hemodialysis therapyhttps://orcid.org/0000-0002-8798-887XМарковаТ. Н.MarkovaT. N.

Маркова Татьяна Николаевна, доктор медицинских наук, доцент, профессор

Москва

eLibrary SPIN: 5914-2890

Tatyana N. Markova, MD, PhD, Professor

Moscow

eLibrary SPIN: 5914-2890

markovatn18@yandex.ruhttps://orcid.org/0000-0001-8062-7847ЯворскаяВ. О.YavorskayaV. O.

Яворская Виктория Олеговна, аспирант

127473, Москва, ул. Делегатская, д. 20, стр. 1

Victoria O. Yavorskaya, PhD student, endocrinologist

20/1 Delegatskaja street, Moscow, 127473

victoria.tsuprova@gmail.comМосковский государственный медико-стоматологический университет имени А.И. Евдокимова; Городская клиническая больница №52РоссияMoscow State University of Medicine and Dentistry named after A.I. Evdokimov; Moscow City Hospital 52Russian FederationМосковский государственный медико-стоматологический университет имени А.И. ЕвдокимоваРоссияMoscow State University of Medicine and Dentistry named after A.I. EvdokimovRussian Federation202229082022254388394Copyright © Маркова Т.Н., Яворская В.О., 20222022Маркова Т.Н., Яворская В.О.Markova T.N., Yavorskaya V.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12920

На сегодня достаточно много научных работ, посвященных роли нарушений углеводного обмена (НУО) в развитии терминальной хронической почечной недостаточности (тХПН), в то же время остается малоизученным вопрос влияния хронической болезни почек (ХБП) на развитие углеводных сдвигов, особенно у больных на заместительной почечной терапии (ЗПТ). Ежегодное неуклонное возрастание количества пациентов с тХПН без сахарного диабета (СД), нуждающихся в диализной терапии, приводит к увеличению интереса и необходимости изучения углеводного статуса у данных пациентов. Известно, что гипергликемия у больных без СД на гемодиализе (ГД) является предрасполагающим фактором к развитию сердечно-сосудистых катастроф, ухудшающих качество жизни, а также увеличивающих смертность. Особенности метаболизма глюкозы у пациентов, получающих ЗПТ, не всегда позволяют адекватно оценить углеводный статус с помощью гликированного гемоглобина (HbA1c). В обзоре представлена актуальная информация по распространенности НУО у пациентов с терминальной ХБП без CД, получающих ЗПТ ГД, затронуты вопросы особенностей метаболизма глюкозы, интерпретации значений HbA1c и гликированного альбумина, риска смертности у гемодиализных пациентов с различными НУО.

There are quite a lot of scientific works today dedicated to the role of disorders carbohydrate metabolism (DCM) in the development of end-stage renal disease (ESRD), at the same time, the influence of chronic kidney disease (CKD) on the development of carbohydrate disorders remains insufficiently studied, especially in patients on renal replacement therapy (RRT). The annual steady increase in the number of patients with ESRD without diabetes mellitus (DM) requiring dialysis therapy leads to increased interest and the need to study carbohydrate status in these patients. It is known that hyperglycemia in patients without DM on hemodialysis (HD) is a predisposing factor to the development of cardiovascular accidents that worsen the quality of life and also increase mortality. The peculiarities of glucose metabolism in patients receiving RRT do not always allow adequate assessment of carbohydrate status using glycated hemoglobin (HbA1c). The review provides up-to-date information on the prevalence of DCM in patients with ESRD without DM receiving HD RRT, touches upon the peculiarities of glucose metabolism, interpretation of HbA1c and glycated albumin values, and mortality risk in hemodialysis patients with various DCM.

заместительная почечная терапиянарушения углеводного обменахроническая болезнь почексахарный диабетгликированный альбуминrenal replacement therapydisorders of carbohydrate metabolismchronic kidney diseasediabetes mellitusglycated albuminReferencesBoenink R, Astley ME, Huijben JA, et al. The ERA Registry Annual Report 2019: summary and age comparisons. Clin Kidney J. 2022;15(3):452-472. doi: https://doi.org/10.1093/ckj/sfab273Boenink R, Astley ME, Huijben JA, et al. The ERA Registry Annual Report 2019: summary and age comparisons. Clin Kidney J. 2022;15(3):452-472. doi: https://doi.org/10.1093/ckj/sfab273Home USRDS [Internet]. USRDS. 2022 [cited 16 April 2022]. Available from: http://usrds.org/Home USRDS [Internet]. USRDS. 2022 [cited 16 April 2022]. Available from: http://usrds.org/Андрусев А.М., Томилина Н.А., Перегудова Н.Г., Шинкарев М.Б. Заместительная почечная терапия хронической болезни почек 5 стадии в Российской Федерации 2015–2019 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества // Нефрология и диализ. — 2021. — Т. 23. — №3. — С. 255-329. doi: https://doi.org/10.28996/2618980120213255329Andrusev AM, Tomilina NA, Peregudova NG, Shinkarev MB. Kidney replacement therapy for end Stage Kidney Disease in Russian Federation, 2015–2019. Russian National Kidney Replacement Therapy Registry Report of Russian Public Organization of Nephrologists “Russian Dialysis Society”. Nephrologу and Dialуsis. 2021;23(3):255-329. (In Russ.). doi: https://doi.org/10.28996/2618980120213255329Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One. 2016;11(7):e0158765. doi: https://doi.org/10.1371/journal.pone.0158765Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS One. 2016;11(7):e0158765. doi: https://doi.org/10.1371/journal.pone.0158765Lin-Tan D-T, Lin J-L, Wang L-H, et al. Fasting Glucose Levels in Predicting 1-Year All-Cause Mortality in Patients Who Do Not Have Diabetes and Are on Maintenance Hemodialysis. J Am Soc Nephrol. 2007;18(8):2385-2391. doi: https://doi.org/10.1681/ASN.2006121409Lin-Tan D-T, Lin J-L, Wang L-H, et al. Fasting Glucose Levels in Predicting 1-Year All-Cause Mortality in Patients Who Do Not Have Diabetes and Are on Maintenance Hemodialysis. J Am Soc Nephrol. 2007;18(8):2385-2391. doi: https://doi.org/10.1681/ASN.2006121409DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):514. doi: https://doi.org/10.1111/j.14631326.2011.01511.xDeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):514. doi: https://doi.org/10.1111/j.14631326.2011.01511.xМкртумян А.М., Маркова Т.Н., Мищенко Н.К. Роль почек в гомеостазе глюкозы // Проблемы Эндокринологии. — 2017. — Т. 63. — №6. — С. 385-391. doi: https://doi.org/10.14341/probl2017636385-391Mkrtumyan A.M., Markova T.N., Mishchenko N.K. The role of the kidneys in glucose homeostasis. Problems of Endocrinology. 2017;63(6):385-391. (In Russ.). doi: https://doi.org/10.14341/probl2017636385-391Legouis D, Faivre A, Cippà PE, de Seigneux S. Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism. Nephrol Dial Transplant. 2022;37(8):1417-1425. doi: https://doi.org/10.1093/ndt/gfaa302Legouis D, Faivre A, Cippà PE, de Seigneux S. Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism. Nephrol Dial Transplant. 2022;37(8):1417-1425. doi: https://doi.org/10.1093/ndt/gfaa302Rhee CM, Kovesdy CP, Kalantar-Zadeh K. Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease. Semin Nephrol. 2021;41(2):96-103. doi: https://doi.org/10.1016/j.semnephrol.2021.03.004Rhee CM, Kovesdy CP, Kalantar-Zadeh K. Glucose Homeostasis, Hypoglycemia, and the Burnt-Out Diabetes Phenomenon in Kidney Disease. Semin Nephrol. 2021;41(2):96-103. doi: https://doi.org/10.1016/j.semnephrol.2021.03.004Moen MF, Zhan M, Hsu VD, et al. Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2009;4(6):1121-1127. doi: https://doi.org/10.2215/CJN.00800209Moen MF, Zhan M, Hsu VD, et al. Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2009;4(6):1121-1127. doi: https://doi.org/10.2215/CJN.00800209Xu H, Carrero JJ. Insulin resistance in chronic kidney disease. Nephrology. 2017;22(6):31-34. doi: https://doi.org/10.1111/nep.13147Xu H, Carrero JJ. Insulin resistance in chronic kidney disease. Nephrology. 2017;22(6):31-34. doi: https://doi.org/10.1111/nep.13147Guthoff M, Wagner R, Vosseler D, et al. Impact of end-stage renal disease on glucose metabolism—a matched cohort analysis. Nephrol Dial Transplant. 2017;32(4):670-676. doi: https://doi.org/10.1093/ndt/gfx018Guthoff M, Wagner R, Vosseler D, et al. Impact of end-stage renal disease on glucose metabolism—a matched cohort analysis. Nephrol Dial Transplant. 2017;32(4):670-676. doi: https://doi.org/10.1093/ndt/gfx018Landau M, Kurella-Tamura M, Shlipak MG, et al. Correlates of insulin resistance in older individuals with and without kidney disease. Nephrol Dial Transplant. 2011;26(9):2814-2819. doi: https://doi.org/10.1093/ndt/gfq817Landau M, Kurella-Tamura M, Shlipak MG, et al. Correlates of insulin resistance in older individuals with and without kidney disease. Nephrol Dial Transplant. 2011;26(9):2814-2819. doi: https://doi.org/10.1093/ndt/gfq817Duong T Van, Shih C-K, Wong T-C, et al. Insulin Resistance and Cardiovascular Risks in Different Groups of Hemodialysis Patients: A Multicenter Study. Biomed Res Int. 2019;2019(9):1-9. doi: https://doi.org/10.1155/2019/1541593Duong T Van, Shih C-K, Wong T-C, et al. Insulin Resistance and Cardiovascular Risks in Different Groups of Hemodialysis Patients: A Multicenter Study. Biomed Res Int. 2019;2019(9):1-9. doi: https://doi.org/10.1155/2019/1541593Dimitrijevic Z, Jovanovic A, Cvetkovic M, et al. Associations of Cardiovascular and All-Cause Mortality with Metabolic Syndrome in Hemodialysis Patients: A Prospective Single-Center Study. Medicina. 2019;55(10):694. doi: https://doi.org/10.3390/medicina55100694Dimitrijevic Z, Jovanovic A, Cvetkovic M, et al. Associations of Cardiovascular and All-Cause Mortality with Metabolic Syndrome in Hemodialysis Patients: A Prospective Single-Center Study. Medicina. 2019;55(10):694. doi: https://doi.org/10.3390/medicina55100694Bi X, Ai H, Wu Q, et al. Insulin Resistance Is Associated with Interleukin 1β (IL-1β) in Non-Diabetic Hemodialysis Patients. Med Sci Monit. 2018;24(10):897-902. doi: https://doi.org/10.12659/MSM.906269Bi X, Ai H, Wu Q, et al. Insulin Resistance Is Associated with Interleukin 1β (IL-1β) in Non-Diabetic Hemodialysis Patients. Med Sci Monit. 2018;24(10):897-902. doi: https://doi.org/10.12659/MSM.906269Yun H-R, Kim H, Park JT, et al. Obesity, Metabolic Abnormality, and Progression of CKD. Am J Kidney Dis. 2018;72(3):400-410. doi: https://doi.org/10.1053/j.ajkd.2018.02.362Yun H-R, Kim H, Park JT, et al. Obesity, Metabolic Abnormality, and Progression of CKD. Am J Kidney Dis. 2018;72(3):400-410. doi: https://doi.org/10.1053/j.ajkd.2018.02.362Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015;11(5):302-313. doi: https://doi.org/10.1038/nrneph.2015.38Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015;11(5):302-313. doi: https://doi.org/10.1038/nrneph.2015.38Johnson S, Crane PB, Neil J, Christiano C. Coping with Intradialytic Events and Stress Associated with Hemodialysis. Nephrol Nurs J. 2019;46(1):1321Johnson S, Crane PB, Neil J, Christiano C. Coping with Intradialytic Events and Stress Associated with Hemodialysis. Nephrol Nurs J. 2019;46(1):1321Wu P-P, Kor C-T, Hsieh M-C, Hsieh Y-P. Association between EndStage Renal Disease and Incident Diabetes Mellitus—A Nationwide Population-Based Cohort Study. J Clin Med. 2018;7(10):343. doi: https://doi.org/10.3390/jcm7100343Wu P-P, Kor C-T, Hsieh M-C, Hsieh Y-P. Association between EndStage Renal Disease and Incident Diabetes Mellitus—A Nationwide Population-Based Cohort Study. J Clin Med. 2018;7(10):343. doi: https://doi.org/10.3390/jcm7100343Khan AHKY, Zakaria NF, Abidin MAZ, Lim CTS, Kamaruddin NA. Glycemic Patterns and Factors Associated with Post-Hemodialysis Hyperglycemia among End-Stage Renal Disease Patients undergoing Maintenance Hemodialysis. J ASEAN Fed Endocr Soc. 2020;35(1):68-76. doi: https://doi.org/10.15605/jafes.035.01.12Khan AHKY, Zakaria NF, Abidin MAZ, Lim CTS, Kamaruddin NA. Glycemic Patterns and Factors Associated with Post-Hemodialysis Hyperglycemia among End-Stage Renal Disease Patients undergoing Maintenance Hemodialysis. J ASEAN Fed Endocr Soc. 2020;35(1):68-76. doi: https://doi.org/10.15605/jafes.035.01.12Jean G, Souberbielle J, Chazot C. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients. 2017;9(4):328. doi: https://doi.org/10.3390/nu9040328Jean G, Souberbielle J, Chazot C. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients. 2017;9(4):328. doi: https://doi.org/10.3390/nu9040328Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation [Internet]. PubMed. 2022 [cited 16 April 2022]. Available from: https://pubmed.ncbi.nlm.nih.gov/26158184/Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation [Internet]. PubMed. 2022 [cited 16 April 2022]. Available from: https://pubmed.ncbi.nlm.nih.gov/26158184/American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2021 [published correction appears in Diabetes Care. 2021;44(9)]. Diabetes Care. 2021;44(S1):S15-S33. doi: https://doi.org/10.2337/dc21-S002American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2021 [published correction appears in Diabetes Care. 2021;44(9)]. Diabetes Care. 2021;44(S1):S15-S33. doi: https://doi.org/10.2337/dc21-S002Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (10-й выпуск) // Сахарный диабет. — 2021. — Т. 24. — №S1. — С.1-235. doi: https://doi.org/10.14341/DM12802Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2021;24(S1):1-235 (In Russ.). doi: https://doi.org/10.14341/DM12802Sofue T, Nakagawa N, Kanda E, et al. Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, crosssectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One. 2020;15(7):e0236132. doi: https://doi.org/10.1371/journal.pone.0236132Sofue T, Nakagawa N, Kanda E, et al. Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, crosssectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One. 2020;15(7):e0236132. doi: https://doi.org/10.1371/journal.pone.0236132Vos FE, Schollum JB, Coulter CV, et al. Red Blood Cell Survival in Long-term Dialysis Patients. Am J Kidney Dis. 2011;58(4):591-598. doi: https://doi.org/10.1053/j.ajkd.2011.03.031Vos FE, Schollum JB, Coulter CV, et al. Red Blood Cell Survival in Long-term Dialysis Patients. Am J Kidney Dis. 2011;58(4):591-598. doi: https://doi.org/10.1053/j.ajkd.2011.03.031Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int. 2001;59:S67-S72. doi: https://doi.org/10.1046/j.1523-1755.2001.59780067.xMacdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int. 2001;59:S67-S72. doi: https://doi.org/10.1046/j.1523-1755.2001.59780067.xСтроков А.Г., Гуревич К.Я., Ильин А.П., и др. Лечение пациентов с хронической болезнью почек 5 стадии (ХБП 5) методами гемодиализа и гемодиафильтрации. Клинические рекомендации // Нефрология. — 2017. — Т. 21. — №3. — С. 92-111. doi: https://doi.org/10.24884/1561-6274-2017-3-92-111Strokov GA, Gurevich KY, Ilyin AP, et al. Treatment of patients with chronic kidney disease stage 5 (CKD 5) by hemodialysis and hemodiafiltration. Clinical guidelines. Nephrology (Saint-Petersburg). 2017;21(3):92-111. (In Russ.). doi: https://doi.org/10.24884/1561-6274-2017-3-92-111Ok ES, Asci G, Toz H, et al. Glycated hemoglobin predicts overall and cardiovascular mortality in non-diabetic hemodialysis patients. Clin Nephrol. 2014;82(09):173-180. doi: https://doi.org/10.5414/CN108251Ok ES, Asci G, Toz H, et al. Glycated hemoglobin predicts overall and cardiovascular mortality in non-diabetic hemodialysis patients. Clin Nephrol. 2014;82(09):173-180. doi: https://doi.org/10.5414/CN108251Abe M, Hamano T, Hoshino J, et al. Is there a “burnt-out diabetes” phenomenon in patients on hemodialysis? Diabetes Res Clin Pract. 2017;130(09):211-220. doi: https://doi.org/10.1016/j.diabres.2017.06.012Abe M, Hamano T, Hoshino J, et al. Is there a “burnt-out diabetes” phenomenon in patients on hemodialysis? Diabetes Res Clin Pract. 2017;130(09):211-220. doi: https://doi.org/10.1016/j.diabres.2017.06.012Schexnayder CD, Agbahiwe S, Emelogu O. Burnt Out? The Phenomenon of Type 2 Diabetes Mellitus in End-Stage Renal Disease. Fed Pract. 2020 Dec;37(12):580-585. doi: https://doi.org/10.12788/fp.0076.Schexnayder CD, Agbahiwe S, Emelogu O. Burnt Out? The Phenomenon of Type 2 Diabetes Mellitus in End-Stage Renal Disease. Fed Pract. 2020 Dec;37(12):580-585. doi: https://doi.org/10.12788/fp.0076.Martino FG, Vitillo M, Pieri M, et al. Biomarkers of Glyco-Metabolic Control in Hemodialysis Patients: Glycated Hemoglobin vs. Glycated Albumin. Medicina (Kaunas). 2021;57(7):712. doi: https://doi.org/10.3390/medicina57070712Martino FG, Vitillo M, Pieri M, et al. Biomarkers of Glyco-Metabolic Control in Hemodialysis Patients: Glycated Hemoglobin vs. Glycated Albumin. Medicina (Kaunas). 2021;57(7):712. doi: https://doi.org/10.3390/medicina57070712Duan N, Zhu SN, Li HX, et al. Assessment of Glycated Albumin as a Useful Indicator for Renal Dysfunction in Diabetic and Nondiabetic Population. Clin Lab. 2017;63(7):1129-1137. doi: https://doi.org/10.7754/Clin.Lab.2017.161224Duan N, Zhu SN, Li HX, et al. Assessment of Glycated Albumin as a Useful Indicator for Renal Dysfunction in Diabetic and Nondiabetic Population. Clin Lab. 2017;63(7):1129-1137. doi: https://doi.org/10.7754/Clin.Lab.2017.161224Huang C, Guo Q, Duan N, et al. Baseline Glycated Albumin Predicts the Renal Dysfunction in a Five-Year Prospective Population-Based Study. Clin Lab. 2020;66(07/2020). doi: https://doi.org/10.7754/Clin.Lab.2019.190634Huang C, Guo Q, Duan N, et al. Baseline Glycated Albumin Predicts the Renal Dysfunction in a Five-Year Prospective Population-Based Study. Clin Lab. 2020;66(07/2020). doi: https://doi.org/10.7754/Clin.Lab.2019.190634Ma WY, Wu CC, Pei D, et al. Glycated albumin is independently associated with estimated glomerular filtration rate in nondiabetic patients with chronic kidney disease. Clin Chim Acta. 2011;412(78):583-586. doi: https://doi.org/10.1016/j.cca.2010.12.013Ma WY, Wu CC, Pei D, et al. Glycated albumin is independently associated with estimated glomerular filtration rate in nondiabetic patients with chronic kidney disease. Clin Chim Acta. 2011;412(78):583-586. doi: https://doi.org/10.1016/j.cca.2010.12.013Okada T, Nakao T, Matsumoto H, et al. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease. Intern Med. 2011;50(1):23-29. doi: https://doi.org/10.2169/internalmedicine.50.4129Okada T, Nakao T, Matsumoto H, et al. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease. Intern Med. 2011;50(1):23-29. doi: https://doi.org/10.2169/internalmedicine.50.4129Dozio E, Corradi V, Proglio M, et al. Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). Diabetes Res Clin Pract. 2018;140:9-17. doi: https://doi.org/10.1016/j.diabres.2018.03.017Dozio E, Corradi V, Proglio M, et al. Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). Diabetes Res Clin Pract. 2018;140:9-17. doi: https://doi.org/10.1016/j.diabres.2018.03.017Yarragudi R, Gessl A, Vychytil A. New-Onset Diabetes Mellitus in Peritoneal Dialysis and Hemodialysis Patients: Frequency, Risk Factors, and Prognosis. A Review. Ther Apher Dial. 2019;23(6):497-506. doi: https://doi.org/10.1111/17449987.12800Yarragudi R, Gessl A, Vychytil A. New-Onset Diabetes Mellitus in Peritoneal Dialysis and Hemodialysis Patients: Frequency, Risk Factors, and Prognosis. A Review. Ther Apher Dial. 2019;23(6):497-506. doi: https://doi.org/10.1111/17449987.12800Hsieh C-Y, Su C-C, Shao S-C, et al. Taiwan’s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349-358. doi: https://doi.org/10.2147/CLEP.S196293Hsieh C-Y, Su C-C, Shao S-C, et al. Taiwan’s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349-358. doi: https://doi.org/10.2147/CLEP.S196293Tien K-J, Lin Z-Z, Chio C-C, et al. Epidemiology and Mortality of NewOnset Diabetes After Dialysis. Diabetes Care. 2013;36(10):3027-3032. doi: https://doi.org/10.2337/dc12-2148Tien K-J, Lin Z-Z, Chio C-C, et al. Epidemiology and Mortality of NewOnset Diabetes After Dialysis. Diabetes Care. 2013;36(10):3027-3032. doi: https://doi.org/10.2337/dc12-2148Chou C-Y, Liang C-C, Kuo H-L, et al. Comparing Risk of New Onset Diabetes Mellitus in Chronic Kidney Disease Patients Receiving Peritoneal Dialysis and Hemodialysis Using Propensity Score Matching. PLoS One. 2014;9(2):e87891. doi: https://doi.org/10.1371/journal.pone.0087891Chou C-Y, Liang C-C, Kuo H-L, et al. Comparing Risk of New Onset Diabetes Mellitus in Chronic Kidney Disease Patients Receiving Peritoneal Dialysis and Hemodialysis Using Propensity Score Matching. PLoS One. 2014;9(2):e87891. doi: https://doi.org/10.1371/journal.pone.0087891Salifu MO, Abbott KC, Aytug S, et al. New-Onset Diabetes after Hemodialysis Initiation: Impact on Survival. Am J Nephrol. 2010;31(3):239-246. doi: https://doi.org/10.1159/000276542Salifu MO, Abbott KC, Aytug S, et al. New-Onset Diabetes after Hemodialysis Initiation: Impact on Survival. Am J Nephrol. 2010;31(3):239-246. doi: https://doi.org/10.1159/000276542Wang IK, Lin CL, Chen HC, et al. Risk of new-onset diabetes in end-stage renal disease patients undergoing dialysis: analysis from registry data of Taiwan. Nephrol Dial Transplant. 2018;33(4):670-675. doi: https://doi.org/10.1093/ndt/gfx250Wang IK, Lin CL, Chen HC, et al. Risk of new-onset diabetes in end-stage renal disease patients undergoing dialysis: analysis from registry data of Taiwan. Nephrol Dial Transplant. 2018;33(4):670-675. doi: https://doi.org/10.1093/ndt/gfx250Ahmadmehrabi S, Tang WHW. Hemodialysis-induced cardiovascular disease. Semin Dial. 2018;31(3):258-267. doi: https://doi.org/10.1111/sdi.12694Ahmadmehrabi S, Tang WHW. Hemodialysis-induced cardiovascular disease. Semin Dial. 2018;31(3):258-267. doi: https://doi.org/10.1111/sdi.12694

The authors declare that there are no conflicts of interest present.